Latest news with #Rule15c2-11
Business Wire
01-07-2025
- Business
- Business Wire
BP Prudhoe Bay Royalty Trust Announces No Unit Payment for the Second Quarter of 2025 and Update on NYSE Delisting
HOUSTON--(BUSINESS WIRE)--BP Prudhoe Bay Royalty Trust (NYSE: BPT) announced that Unit holders of record on July 15, 2025 will not receive a dividend payment for the quarter ended June 30, 2025. As provided in the Trust Agreement, a quarterly royalty payment by Hilcorp North Slope, LLC to the Trust is the sum of the individual revenues attributed to the Trust as calculated each day during the quarter. The amount of revenue is determined by multiplying Royalty Production for each day in the calendar quarter by the Per Barrel Royalty for that day. Pursuant to the Trust Agreement, the Per Barrel Royalty for any day is the WTI Price for the day less the sum of (i) Chargeable Costs multiplied by the Cost Adjustment Factor and (ii) Production Taxes. For the three months ended June 30, 2025, the Per Barrel Royalty was calculated based on the following information: The average daily closing WTI price was below the 'break-even' price for the quarter, resulting in a negative value for the payment calculation for the quarter. However, as provided in the Trust Agreement, the payment with respect to the Royalty Interest for any calendar quarter may not be less than zero. As previously disclosed, the Trust terminated at 11:59 PM on December 31, 2024, and The Bank of New York Mellon Trust Company, N.A., as trustee (the 'Trustee'), has commenced the process of winding up the affairs of the Trust. The Trustee cannot predict when the wind-up of the Trust will be completed. Delisting from NYSE The Trust also announced that on June 30, 2025, it had received notification from the New York Stock Exchange ('NYSE') of its determination to suspend trading of the Trust's units of beneficial interest (the 'Units'), effective as of the close of trading on June 30, 2025, and to initiate proceedings to delist the Units. The determination to commence the delisting proceeding results from the Trust's inability to satisfy the continued listing compliance standards set forth under Rule 802.01C of the NYSE Listed Company Manual because the average closing price of the Units fell below $1.00 over a 30 consecutive trading-day period that ended on December 30, 2024, and the Trust was unable to regain compliance with the applicable standards within a cure period that concluded on June 30, 2025. As a result of the suspension, the Units began trading on July 1, 2025, under the symbol 'BPPTU' on the Pink Limited Market ('OTC Pink'), which is operated by OTC Markets Group, Inc. To be quoted on OTC Pink, a market maker must sponsor the security and comply with SEC Rule 15c2-11 before it can initiate a quote in a specific security. OTC Pink is a significantly more limited market than the NYSE, and the quotation of the Units on OTC Pink may result in a less liquid market available for existing and potential unitholders and could further depress the trading price of the Units. There is no assurance that an active market in the Units will develop on OTC Pink. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release are subject to a number of risks and uncertainties beyond the control of the Trust. These forward-looking statements include the Trust's expectations regarding the timing of the transition of the quotation of the Units to OTC Pink, expectations regarding the trading of the Units on OTC Pink and the Trust asset sale process. Descriptions of some of the risks that could affect the future performance of the Trust appear in the Trust's Annual Report on Form 10-K for the year ended December 31, 2024, the Trust's subsequent Quarterly Reports on Form 10-Q, and the Trust's other filings with the Securities and Exchange Commission (the 'SEC'). The Trust's annual, quarterly and other filed reports are or will be available over the Internet at the SEC's website at The Trustee undertakes no obligation to update forward-looking statements after the date of this report, except as required by law, and all such forward-looking statements in this report are qualified in their entirety by the preceding cautionary statements.
Yahoo
04-06-2025
- Business
- Yahoo
KRTL Holding Group Inc. Advances in 15c2-11 Process with Court-Approved Shareholder Verification Initiative
Lakewood, CO, June 04, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE KRTL Holding Group Inc. Advances in 15c2-11 Process with Court-Approved Shareholder Verification Initiative KRTL Holding Group Inc. (OTC: KRTL) announces a significant advancement in its journey toward full compliance with SEC Rule 15c2-11. Following a comprehensive review of legacy shareholder records predating KRTL's acquisition and restructuring, the company has successfully obtained a court order from the Third Judicial District Court, Salt Lake County, Utah. This order authorizes KRTL to initiate a structured, court-supervised verification and remediation process of legacy shareholders. Court-Approved Shareholder Verification Process Under the terms of the court order dated May 27, 2025, KRTL has commenced a rigorous program to: Send certified, court-approved notices to shareholders listed in historical records, requesting verifiable proof of ownership. Provide a 60-day window for shareholders to submit acceptable documentation, including government-issued identification and proof of stock ownership. Petition for the cancellation of shares tied to non-responsive or unverifiable shareholders through judicial declaration. Allow for discretionary reissuance in cases where late verification is provided, maintaining corporate governance standards. This proactive step is a major milestone in KRTL's efforts to cleanse its shareholder records of fictitious or unverified entries—a critical component to comply with SEC Rule 15c2-11 which governs the public quoting of OTC securities, and to facilitate Rule 144 resale eligibility, which requires a clear chain of ownership. What This Means for Our Shareholders and the Company For current and prospective shareholders, this initiative ensures a more transparent and trustworthy shareholder base. By removing legacy uncertainties, KRTL strengthens its corporate governance and enhances the integrity of its shareholder records, providing a strong foundation for future growth and regulatory standing. For KRTL, this action accelerates the company's compliance efforts with FINRA and SEC requirements, moving it significantly closer to achieving full Rule 15c2-11 compliance, a key milestone in reestablishing public market quotation and increasing shareholder value. Commitment to Transparency and Compliance 'This is a pivotal moment for KRTL Holding Group,' said Cesar Herrera, CEO of KRTL Holding Group Inc. 'We are taking decisive action to ensure the accuracy of our shareholder records and to align our operations with the highest standards of regulatory compliance. By resolving these legacy issues, we aim to restore confidence in our shareholder registry and pave the way toward improved trading access and long-term value creation.' About KRTL Holding Group Inc. KRTL Holding Group Inc. (OTC: KRTL) operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp. The Company leverages strategic synergies across industries to pursue investments, mergers, and partnerships that deliver shareholder value. Focused on biotech, technology, and emerging market opportunities, KRTL Holding Group is committed to growth, innovation, and operational excellence. Additional information on KRTL is available online at and and This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as "anticipates," "believes," "plans," "expects," "intends," "projects," "estimates," "future," and "opportunity" and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company's filings. Additional information concerning risks and uncertainties that could materially affect KRTL's business and financial results is included in the Company's filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. CONTACT: info@ info@ info@ in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT. Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Market, effective today. This milestone, achieved in an unprecedented six weeks from the filing date of April 2nd, 2025, alongside the completion of SEC Rule 15c2-11 compliance, reinforces Adia's commitment to transparency, investor accessibility, and delivering on its promises with remarkable speed. OTCQB Uplisting To view an enhanced version of this graphic, please visit: The OTCQB uplisting process, which typically takes companies an average of 12-16 weeks from filing to approval, was executed by Adia Nutrition with exceptional efficiency. This rapid timeline-less than half the industry norm-demonstrates the company's operational excellence and close collaboration with OTC Markets Group, following an independent audit with Astra Audit and Advisory LLC on April 1, 2025. The completion of SEC Rule 15c2-11 compliance is a pivotal achievement, ensuring Adia's financial information is publicly available and meets stringent transparency standards. This rule requires broker-dealers to review and maintain current issuer information before quoting securities, enhancing investor confidence and enabling broader market participation. By satisfying 15c2-11, Adia Nutrition strengthens its credibility, facilitates trading liquidity, and positions itself as a trusted investment opportunity in the regenerative medicine sector. "Uplisting to OTCQB in six weeks and completing 15c2-11 compliance reflect our relentless focus on execution and transparency," said Larry Powalisz, CEO of Adia Nutrition Inc. "We promised our shareholders enhanced visibility, liquidity, and trust, and we've delivered-faster than most. This is yet another goal we set and achieved swiftly, paving the way for our continued growth and our ultimate vision of a Nasdaq Small Cap listing." The OTCQB Venture Market and 15c2-11 compliance elevate Adia Nutrition's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base. This uplisting follows a series of rapid accomplishments, including the removal of the shell risk designation and the opening of its first Florida clinic for regenerative therapies, solidifying Adia's track record of setting ambitious targets and surpassing them. Adia Nutrition remains dedicated to revolutionizing healthcare through its medical division, specializing in umbilical cord stem cell (UCB-SC) therapies, and its supplement division, delivering premium, organic products. The company invites investors and stakeholders to join its journey as it expands its clinic network and drives innovation. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
